SPOTLIGHT -
May 23rd 2023
What is the connection?
May 20th 2023
Petros Levounis, MD, MA, reflects on his upcoming presidency for the American Psychiatric Association.
May 19th 2023
A look at the theme for the 2023 American Psychiatric Association Annual Meeting.
May 12th 2023
"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."
May 9th 2023
Ketamine is relatively new to the average American. What can you share with them as a mental health clinician?
The Week in Review: May 1-5
From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.
Read More
An Imperfect Guide to Crisis Stabilization Units: Matching the Right Level of Care to Individual Needs
Here’s how having a clear understanding of the services different crisis stabilization units provide can help communities serve the unique needs of each individual in crisis without unnecessarily restrictive or intensive levels of care.
From the Pages of Psychiatric Times: April 2023
The experts weighed in on a wide variety of psychiatric issues for the April 2023 issue of Psychiatric Times.
The Week in Review: April 10-14
From to co-occurring substance use and eating disorders to treatment options for OCD, here are highlights from the week in Psychiatric Times.
New SAMHSA CCBHC Criteria Will Foster Innovation in Crisis Services Continuum
The new criteria have been updated to increase flexibility and provide greater clarity around standards for behavioral health clinicians.
Co-occurring Substance Use and Eating Disorders
What does existing research say about the connection between substance use disorders and eating disorders?
The Week in Review: April 3-7
From over-the-counter naloxone to the true connection between gun violence and mental illness, here are highlights from the week in Psychiatric Times.
Over-the-Counter Naloxone: A Step in the Right Direction?
Psychiatric Times’ Substance Use Section Editor weighs in on the FDA approval of the first naloxone product for nonprescription use.
The Week in Review: March 27-31
From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.
FDA Approves First Naloxone Product for Over-the-Counter Use
The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients.
The Week in Review: March 20-24
From collaborative care for individuals with schizophrenia and COVID-19 to strategies for building patient rapport, here are highlights from the week in Psychiatric Times.
Physical and Mental Health Status in Bipolar Disorder Based on Smoking Status
What are the psychiatric and non-psychiatric correlates of tobacco smoking status in bipolar disorders? Researchers investigated these associations in a large patient cohort.
ADHD and Smoking Cessation Outcomes With Varenicline
Do ADHD symptoms impact smoking cessation outcomes? Researchers performed a randomized controlled trial of varenicline for tobacco cessation in adolescents and young adults.
Research Analyzes Caffeine Intake and Levels in Smokers With Bipolar Disorder and Schizophrenia
Caffeine use is higher in smokers and in adults with serious mental illness. How does this impact patients with bipolar disorder and schizophrenia?
Thoughts About the Overdose Conundrum
One doctor’s experience with patient suicide.
The “Unwinding” of the Medicaid Continuous Enrollment Condition: 3 Things to Know
Patients with serious mental illness and substance use disorders are expected to be particularly affected by these changes.
The Week in Review: February 6-10
From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.
The Overdose Conundrum
A patient loss does not undo or discard the multitude of meaningful life changing and life preserving work done.
Keep the Cart Behind the Horse: Privilege and Responsibility as a Provider
Remember to keep the cart behind the horse while practicing medicine.
Caffeine Intake and Levels in Smokers With Schizophrenia and Bipolar Disorder
Smoking and drinking (caffeine): Researchers analyzed caffeine intake and levels in smokers with schizophrenia and bipolar disorder.
The Year in CMEs
Revisiting the CME articles featured in Psychiatric Times in 2022.
Current Treatments for Cannabis Use Disorder
While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence. Learn more in this CME article.
The Week in Review: December 12-16
From new legislation that would expand the US approach to mental health to drug abuse trends and treatment approaches for 2023, here are highlights from the week in Psychiatric Times.
Drug Abuse Trends and Treatment Approaches for 2023
What are the most pertinent drug trends to be aware of in 2023?
Assessing 2022: What’s the Prognosis in Psychiatry?
Survey Finds 1 in 7 Physicians Uses Alcohol or Drugs on the Job to Cope With Stress
"We must put mental health on par with physical health and make it a basic human right, an indicator of overall health, and an industry standard.”
The Road to Over-the-Counter Naloxone: FDA Releases Federal Register Notice
We may be one step closer to nonprescription naloxone.
Decriminalizing Mental Health: Partnering With Law Enforcement to Reduce Unwanted Outcomes
How can PMHNP consults with law enforcement reduce involuntary transfers and other unwanted outcomes?
Clinicians Embracing a Recovery Mindset: Mirroring Recovery to People You Serve
What is recovery?
Understanding the Long-Term Clinical Course of Comorbid SUD and ADHD
Comorbid SUD and ADHD is associated with more severe illness. What do we understand about these comorbid conditions and what do we still need to learn?
